Literature DB >> 2488184

Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD).

S J Davies1, C S Ogg, J S Cameron, S Poston, W C Noble.   

Abstract

Over a three-year period, 217 episodes of bacterial peritonitis occurred in 183 patient years. Thirty-seven episodes were due to Staphylococcus aureus and 19 (51%) of these required removal of the catheter to eradicate infection. This compared with catheter loss in 4/63 (6.3%) coagulase negative staphylococci infections (p less than 0.001); 7/67 (9.5%) culture negative peritonitis (p less than 0.001); and 10/30 (33.3%) episodes due to gram-negative organisms (p less than 0.05). Over half (51.3%) the episodes due to S. aureus were associated with exit-site infections, and this rose to 100% (10/10) with recurrent peritonitis (p less than 0.01). A prospective analysis of nasal carriage and exit-site infections due to S. aureus was carried out in 87 patients. Exit-site infections were present in 21 (24%), almost entirely due to different strains as judged by sensitivity patterns and phage typing. Nasal carriage, defined as two positive swabs within the study period, was present in 20 (23%) patients. Fourteen (70%) of these had exit-site infections due to the same strain as that isolated from the nose, whereas no patient grew different strains from either site. Nasal carriage increased the risk of infection sixfold (p less than 0.001).

Entities:  

Mesh:

Year:  1989        PMID: 2488184

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  16 in total

Review 1.  Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks.

Authors:  J Kluytmans; A van Belkum; H Verbrugh
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Gentamicin-resistant infections in peritoneal dialysis patients using topical gentamicin exit-site prophylaxis: a report of two cases.

Authors:  Sharon J Nessim; Sarbjit Vanita Jassal
Journal:  Perit Dial Int       Date:  2012 May-Jun       Impact factor: 1.756

Review 3.  A qualitative systematic review of the literature supporting a causal relationship between exit-site infection and subsequent peritonitis in patients with end-stage renal disease treated with peritoneal dialysis.

Authors:  Anouk T N van Diepen; Sarbjit V Jassal
Journal:  Perit Dial Int       Date:  2013 Nov-Dec       Impact factor: 1.756

4.  Exit-Site Dressing and Infection in Peritoneal Dialysis: A Randomized Controlled Pilot Trial.

Authors:  Lily Mushahar; Lim Wei Mei; Wan Shaariah Yusuf; Sudhaharan Sivathasan; Norilah Kamaruddin; Nor Juliana Mohd Idzham
Journal:  Perit Dial Int       Date:  2015-09-15       Impact factor: 1.756

5.  Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis.

Authors:  A Pignatari; M Pfaller; R Hollis; R Sesso; I Leme; L Herwaldt
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

6.  Staphylococcus aureus Colonization and Nosocomial Infections: Implications for Prevention.

Authors:  Philip M Polgreen; Loreen A Herwaldt
Journal:  Curr Infect Dis Rep       Date:  2004-12       Impact factor: 3.725

Review 7.  Host defences in continuous ambulatory peritoneal dialysis and the genesis of peritonitis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

8.  Effect of rifampin on Staphylococcus aureus colonization in children on chronic peritoneal dialysis.

Authors:  C D Hanevold; M C Fisher; R Waltz; S Bartosh; H J Baluarte
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

Review 9.  Microbiological aspects of peritonitis associated with continuous ambulatory peritoneal dialysis.

Authors:  A von Graevenitz; D Amsterdam
Journal:  Clin Microbiol Rev       Date:  1992-01       Impact factor: 26.132

10.  Association between Staphylococcus aureus nasopharyngeal colonization and septicemia in patients infected with the human immunodeficiency virus.

Authors:  T Weinke; R Schiller; F J Fehrenbach; H D Pohle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.